These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9290461)

  • 1. Enhanced deoxyribonucleic acid damage and repair but unchanged apoptosis in uterine leiomyomas treated with gonadotropin-releasing hormone agonist.
    Huang SC; Chou CY; Lin YS; Tsai YC; Hsu KF; Liu CH; Huang KE
    Am J Obstet Gynecol; 1997 Aug; 177(2):417-24. PubMed ID: 9290461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists.
    Nagai K; Asano R; Sekiguchi F; Asai-Sato M; Miyagi Y; Miyagi E
    Am J Obstet Gynecol; 2023 Feb; 228(2):207.e1-207.e9. PubMed ID: 36150519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of parathyroid hormone-related peptide in cell proliferation activity of human uterine leiomyomas.
    Yoshida M; Ohtsuru A; Samejima T; Okazaki M; Fujishita A; Ito M; Yamashita S; Ishimaru T
    Endocr J; 1999 Feb; 46(1):81-90. PubMed ID: 10426571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral blood flow in uterine myoma correlated with a lower tumor size and volume, but not correlated with cell proliferation or angiogenesis.
    Huang SC; Yu CH; Huang RT; Hsu KF; Tsai YC; Chou CY
    Obstet Gynecol; 1996 Jun; 87(6):1019-24. PubMed ID: 8649683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oestrogen deficiency causes DNA damage in uterine leiomyoma cells: a possible mechanism for shrinkage of fibroids by GnRH agonists.
    Cheng YM; Chou CY; Huang SC; Lin HC
    BJOG; 2001 Jan; 108(1):95-102. PubMed ID: 11213012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of cell proliferation and induction of apoptosis in uterine leiomyoma by gonadotropin-releasing hormone agonist (leuprolide acetate).
    Mizutani T; Sugihara A; Nakamuro K; Terada N
    J Clin Endocrinol Metab; 1998 Apr; 83(4):1253-5. PubMed ID: 9543151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular proliferation, estrogen receptor, progesterone receptor, and bcl-2 expression in GnRH agonist-treated uterine leiomyomas.
    Vu K; Greenspan DL; Wu TC; Zacur HA; Kurman RJ
    Hum Pathol; 1998 Apr; 29(4):359-63. PubMed ID: 9563785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphometric and electron-microscopic analyses of the effects of gonadotropin-releasing hormone agonists on uterine leiomyomas.
    Kalir T; Goldstein M; Dottino P; Brodman M; Gordon R; Deligdisch L; Wu H; Gil J
    Arch Pathol Lab Med; 1998 May; 122(5):442-6. PubMed ID: 9593346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of proliferation and up-regulation of apoptosis by gonadotropin-releasing hormone agonist in cultured uterine leiomyoma cells.
    Wang Y; Matsuo H; Kurachi O; Maruo T
    Eur J Endocrinol; 2002 Mar; 146(3):447-56. PubMed ID: 11888853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uterine leiomyosarcoma has deregulated cell proliferation, but not increased microvessel density compared with uterine leiomyoma.
    Chou CY; Huang SC; Tsai YC; Hsu KF; Huang KE
    Gynecol Oncol; 1997 May; 65(2):225-31. PubMed ID: 9159329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gonadotropin-releasing hormone antagonist cetrorelix down-regulates proliferating cell nuclear antigen and epidermal growth factor expression and up-regulates apoptosis in association with enhanced poly(adenosine 5'-diphosphate-ribose) polymerase expression in cultured human leiomyoma cells.
    Chen W; Yoshida S; Ohara N; Matsuo H; Morizane M; Maruo T
    J Clin Endocrinol Metab; 2005 Feb; 90(2):884-92. PubMed ID: 15536154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of gonadotropin-releasing hormone agonist treatment upon angiogenesis in uterine leiomyoma.
    Abulafia O; Kleinhaus K; Levi G; Lee YC; Sherer DM
    Gynecol Obstet Invest; 2001; 52(2):108-13. PubMed ID: 11586038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between platelet-derived growth factor expression in leiomyomas and uterine volume changes after gonadotropin-releasing hormone agonist treatment.
    Di Lieto A; De Rosa G; De Falco M; Iannotti F; Staibano S; Pollio F; Scaramellino M; Salvatore G
    Hum Pathol; 2002 Feb; 33(2):220-4. PubMed ID: 11957148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the karyotype and desoxyribonucleic acid content of uterine myomas in premenopausal, menopausal, and gonadotropin-releasing hormone agonist-treated females.
    Brosens I; Johannisson E; Dal Cin P; Deprest J; Van den Berghe H
    Fertil Steril; 1996 Sep; 66(3):376-9. PubMed ID: 8751732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-step gonadotropin-releasing hormone agonist treatment of uterine leiomyomas: standard-dose therapy followed by reduced-dose therapy.
    Broekmans FJ; Hompes PG; Heitbrink MA; Netelenbos CC; Roos JC; Falke TM; Schoemaker J
    Am J Obstet Gynecol; 1996 Nov; 175(5):1208-16. PubMed ID: 8942490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the inhibitory effect of gonadotropin releasing hormone (GnRH) agonist, selective estrogen receptor modulator (SERM), antiprogesterone on myoma cell proliferation in vitro.
    Chung YJ; Chae B; Kwak SH; Song JY; Lee AW; Jo HH; Lew YO; Kim JH; Kim MR
    Int J Med Sci; 2014; 11(3):276-81. PubMed ID: 24516352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in proliferating and apoptotic markers of leiomyoma following treatment with a selective progesterone receptor modulator or gonadotropin-releasing hormone agonist.
    Yun BS; Seong SJ; Cha DH; Kim JY; Kim ML; Shim JY; Park JE
    Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():62-7. PubMed ID: 26093349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shrinkage effect of gonadotropin releasing hormone agonist treatment on uterine leiomyomas and t(12;14).
    Takahashi K; Kawamura N; Ishiko O; Ogita S
    Int J Oncol; 2002 Feb; 20(2):279-83. PubMed ID: 11788889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance of increased Bcl-2 expression in uterine leiomyomas after GnRH agonist therapy.
    Khurana KK; Singh SB; Tatum AH; Schulz V; Badawy SZ
    J Reprod Med; 1999 Jun; 44(6):487-92. PubMed ID: 10394541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell proliferation and apoptosis in human uterine leiomyomas and myometria.
    Dixon D; Flake GP; Moore AB; He H; Haseman JK; Risinger JI; Lancaster JM; Berchuck A; Barrett JC; Robboy SJ
    Virchows Arch; 2002 Jul; 441(1):53-62. PubMed ID: 12111201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.